The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection
about
New challenges in therapeutic vaccines against HIV infection.Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid).A randomized controlled safety/efficacy trial of therapeutic vaccination in HIV-infected individuals who initiated antiretroviral therapy early in infection.Antitumor in situ vaccination effect of TNFα and IL-12 plasmid DNA electrotransfer in a murine melanoma model.
P2860
The Safety and Immunogenicity of an Interleukin-12-Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
The Safety and Immunogenicity ...... e Treatment of HIV-1 Infection
@ast
The Safety and Immunogenicity ...... e Treatment of HIV-1 Infection
@en
type
label
The Safety and Immunogenicity ...... e Treatment of HIV-1 Infection
@ast
The Safety and Immunogenicity ...... e Treatment of HIV-1 Infection
@en
prefLabel
The Safety and Immunogenicity ...... e Treatment of HIV-1 Infection
@ast
The Safety and Immunogenicity ...... e Treatment of HIV-1 Infection
@en
P2093
P2860
P1476
The Safety and Immunogenicity ...... e Treatment of HIV-1 Infection
@en
P2093
ACTG A5281 Protocol Team
Alan L Landay
Ana L Martinez
Cara C Wilson
David B Clifford
Jeffrey M Jacobson
Jennifer Janik
Jennifer Tiu
John Eldridge
John Hural
P2860
P304
P356
10.1097/QAI.0000000000000830
P407
P577
2016-02-01T00:00:00Z